Press Statements | Page 2 | Pfizer

You are here

Press Statements

10.18.2018

Pfizer Announces Initiation of Phase 3 Trial of Tofacitinib in Patients with Ankylosing Spondylitis

09.12.2018

Terry Bradshaw and Pfizer Encourage Boomers to Understand Their Risk for Pneumococcal Pneumonia and Take Action to Help Prevent It

08.27.2018

Pfizer, Inc. Issues A Voluntary Nationwide Recall Of One Lot Of Children’s Advil® Suspension Bubble Gum Flavored 4 FL OZ Bottle

08.22.2018

Exact Sciences and Pfizer Enter into U.S. Promotion Agreement for Cologuard®

08.21.2018

Important Update on EpiPen® (epinephrine injection, USP) 0.3 mg Auto-Injectors

08.20.2018

Bristol-Myers Squibb-Pfizer Alliance ACROPOLIS™ Real-World Data Program Grows to Sample Size of Nearly One Million Lives Worldwide

08.08.2018

Important Notice Regarding EpiPen Auto-Injector U.S. Supply

07.25.2018

Pfizer Clarifies Incorrect Media Reports Regarding Amsterdam UMC Clinical Trial

07.23.2018

Dr. Seng Hing Cheng appointed Chief Scientific Officer of Pfizer Rare Disease Research Unit

07.10.2018

Pfizer announces it will defer company’s price increases

06.29.2018

Hospira Issues Voluntary Nationwide Recall Of Daptomycin For Injection Lyophilized Powder For Solution, Due to Infusion Reactions

06.04.2018

Hospira Issues A Voluntary Nationwide Recall For Two Lots of Naloxone Hydrochloride Injection, USP, in the Carpuject™ Syringe System Due To The Potential Presence of Particulate Matter.

05.24.2018

Pfizer Reaches $23.85 Million Settlement Agreement To Resolve Allegations Related To Patient Assistance Charities

05.17.2018

Around the World, People Living with Ulcerative Colitis Share Common Perspectives and Experiences

05.09.2018

Important Notice Regarding EpiPen auto-injector supply

04.30.2018

Dawn Rogers Appointed Executive Vice President of Pfizer Worldwide Human Resources

03.05.2018

Hospira Issues A Voluntary Nationwide Recall For Hydromorphone HCL Injection, USP CII Due To The Potential For Empty Or Cracked Glass Vials

02.23.2018

Hospira Issues A Voluntary Nationwide Recall For Labetalol Hydrochloride Injection, USP, Due To The Potential Of Cracked Glass At The Rim Surface Of The Vials

12.11.2017

Pfizer Teams Up with Sickle Cell Disease Community to Launch New Online Platform

11.16.2017

Greenstone Issues Voluntary Nationwide Recall of Diphenoxylate Hydrochloride and Atropine Sulfate Tablets, USP Due to Possible Sub Potent and Super Potent Tablets